The findings with molnupiravir in combination with favipiravir, GS-441524, the protease inhibitor nirmatrelvir, and inhibitors of dihydroorotate dehydrogenase in animal models of COVID-19 [10,39,41,43,44] suggest a potential for clinical development. This evidence concerns the gene DHODH and COVID-19.